Hepatitis B News and Research

Latest Hepatitis B News and Research

Senior UK Parliamentarians visit Bangladesh to see full impact of pneumonia on children

To mark World Pneumonia Day, a senior UK parliamentary delegation travelled to Dhaka this week to see firsthand the full impact of pneumonia on Bangladeshi children.

14 Nov 2011

China Pharma third quarter revenue increases 12% to $21.0 million

China Pharma Holdings, Inc., a specialty pharmaceuticals company in China, today announced financial results for the quarter ended September 30, 2011.

11 Nov 2011

N-acetylcysteine plus cortisone shows promise against acute alcoholic hepatitis

Acute alcoholic hepatitis is one of the most serious forms of alcoholic liver disease, affecting individuals with chronic excessive alcohol consumption, which generally equates to more than 50 grams of alcohol per day, over a period of more than three to six months. The disease is characterized by liver failure and acute jaundice (icterus), which may induce a coma through liver failure and an ensuing death rate of between 40-45% within the first six months.

11 Nov 2011

GenMark Diagnostics third quarter revenues increase 90% to $1.3 million

GenMark Diagnostics, Inc. today reported financial results for the third quarter ended September 30, 2011.

10 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Safe disposal of needles, syringes and other sharps

Many people use needles, syringes and lancets—called "sharps"—to manage their medical conditions at home. These conditions include diabetes, allergies, infertility, arthritis, hepatitis, HIV, blood clotting disorders, migraines and cancer.

9 Nov 2011

Ligand third quarter total revenues decrease to $5.7 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and nine months ended September 30, 2011 and provided a business update.

9 Nov 2011

First-ever phase 1 clinical trial of rectal HIV-prevention drug

A topically applied microbicide gel containing a potent anti-HIV drug has been found to significantly reduce infection when applied to rectal tissue that was subsequently exposed to HIV in the laboratory, according to a new study by the UCLA AIDS Institute.

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011

MBL-HCV1 can reduce viral load in liver transplant patients

A human monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) given to patients with chronic hepatitis C virus (HCV) infection undergoing liver transplantation significantly suppressed the virus for at least a week after transplant and delayed the time to viral rebound.

8 Nov 2011

Economic burden of chronic hepatitis C-related liver disease

Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.

8 Nov 2011

Beware mail order Chicken pox warn Doctors

Doctors have warned against a new trend that has emerged via social networking websites like Facebook - one that guides parents through a process of exposing their children to chicken pox, so that they can get the virus, early and avoid any need for vaccination.

7 Nov 2011

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA, USA.

7 Nov 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex Pharmaceuticals Incorporated today announced positive interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with chronic genotype 1 hepatitis C (HCV) and human immunodeficiency virus.

7 Nov 2011

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

Abbott today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate to severe rheumatoid arthritis (RA) and up to 10 years in patients with long-standing moderate to severe RA, respectively.

7 Nov 2011

New data from Santaris Pharma miravirsen Phase 2a trial on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, presents new data from the Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was maintained for more than four weeks beyond the end of therapy.

6 Nov 2011

$Commercial implants of ALFApump System for refractory ascites performed at Vienna General Hospital$

Commercial implants of ALFApump System for refractory ascites performed at Vienna General Hospital

Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.

5 Nov 2011

Hepatitis B News and Research

Latest Hepatitis B News and Research

Senior UK Parliamentarians visit Bangladesh to see full impact of pneumonia on children

China Pharma third quarter revenue increases 12% to $21.0 million

N-acetylcysteine plus cortisone shows promise against acute alcoholic hepatitis

GenMark Diagnostics third quarter revenues increase 90% to $1.3 million

Idera third quarter net loss increases to $5.5 million

Safe disposal of needles, syringes and other sharps

Ligand third quarter total revenues decrease to $5.7 million

First-ever phase 1 clinical trial of rectal HIV-prevention drug

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

MBL-HCV1 can reduce viral load in liver transplant patients

Economic burden of chronic hepatitis C-related liver disease

Beware mail order Chicken pox warn Doctors

Abbott announces results from HUMIRA Phase 3 study on axSpA

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

New data from Santaris Pharma miravirsen Phase 2a trial on HCV

Commercial implants of ALFApump System for refractory ascites performed at Vienna General Hospital

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Hepatitis B News and Research

Latest Hepatitis B News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in